Innate Pharma SA (IPHA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.33
- As of
Kresmion compiles this page from IPHA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Innate Pharma SA (IPHA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-11-12.
See the full IPHA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IPHA on one page. Preview it with sample data, then open it live with a free account.
Preview the IPHA dossierActive events for IPHA
- mediumEarnings below estimates
Q2-2026: Missed consensus by 380.9%, EPS $-0.34 vs $-0.0707 estimate
- mediumEarnings below estimates
Q2-2019: Missed consensus by 38.1% - EPS $0.2 vs $0.3232 estimate
- mediumEarnings below estimates
Q1-2026: Missed consensus by 240.3% - EPS $-0.55 vs $-0.1616 estimate
FREE, NO ACCOUNT
Every event on IPHA, as it fires
New filings, 13F moves and cross asset events on IPHA land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, IPHA
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
More data on IPHA
IPHA against its peers
IPHA's operating margin of -599.8% ranks in the 58th percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | IPHA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 9.0M EUR | n/a | n/a | 1 |
| Revenue YoY | -55.2% | n/a | n/a | 1 |
| Gross margin | n/a | 64.3% | n/a | 5 |
| Operating margin | -599.8% | -1145.7% | 58 | 12 |
| Net margin | -546.1% | -202.2% | 46 | 13 |
| Return on equity | n/a | -52.8% | n/a | 18 |
| 1 year | -21.5% | -32.0% | 53 | 19 |
Peers (22): TARA, FATE, HUMA, SION, ORMP, UPB, STRO, NAGE, ABEO, ZNTL, YARW, ARMP, ALXO, IVVD, BBOT, IFRX, ACOG, ANTX, NTHI, MENS, MGNX, MSLE. Left out: SCNLD (no annual filing), VRXA (no annual filing), RNA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (IPHA: 20-F), reported in EUR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in IPHA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on IPHA in the last 180 days.
Upstream: SEC EDGAR filings for IPHA
Kresmion, "Innate Pharma SA (IPHA) institutional holdings and SEC filings", data as of 2026-11-12, https://kresmion.com/research/IPHA. Upstream data: SEC EDGAR filings for IPHA.
Link to this data (HTML):
<a href="https://kresmion.com/research/IPHA">Innate Pharma SA (IPHA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow IPHA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to IPHA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.